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Background: The serotonin precursor 5-hydroxy-L-[β-11C]tryptophan ([11C]HTP) is in clinical use for localization of
neuroendocrine tumors and has been suggested as a proxy marker for pancreatic islet cells. However, degradation
by monoamine oxidase-A (MAO-A) reduces retention and the contrast to non-endocrine tissue.
Methods: A synthesis method was developed for 5-hydroxy-L-[β-11C2H]tryptophan ([11C]DHTP), an isotopologue of
[11C]HTP, labeled with 11C and 2H at the β-position adjacent to the carbon involved in MAO-A decarboxylation.
MAO-A-mediated degradation of [11C]DHTP was evaluated and compared to non-deuterated [11C]HTP.
Results: [11C]DHTP was synthesized with a radiochemical purity of >98%, radioactivity of 620 ± 190 MBq, and
deuterium (2H or 2H2) incorporation at the β-position of 22% ±5%. Retention and resistance to MAO-A-mediated
degradation of [11C]DHTP were increased in cells but not in non-human primate pancreas.
Conclusions: Partial deuteration of the β-position yields improved resistance to MAO-A-mediated degradation
in vitro but not in vivo.
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Non-invasive assessment of the serotonergic biosynthesis
by 5-hydroxy-L-[β-11C]tryptophan ([11C]HTP) is an estab-
lished PET marker for many forms of neuroendocrine tu-
mors (NETs) [1] and has recently been suggested as a
surrogate marker for the neuroendocrine pancreas [2-4].
Di Gialleonardo et al. showed that [11C]HTP accumula-
tion in a pancreatic neuroendocrine cell line was signifi-
cantly increased by blocking the major route of degradation,
monoamine oxidase-A (MAO-A) [2]. Furthermore, this
mode of degradation was not present in a ductal cell line.
The authors therefore posit that an HTP analogue, following
the formation of 5-hydroxy-[11C]tryptamine ([11C]5-HT) by
aromatic amino acid decarboxylase (AADC), resistant to
MAO-A-mediated degradation will have an increased reten-
tion in neuroendocrine tissues containing the amine precur-
sor uptake and decarboxylation (APUD) mechanism. APUD* Correspondence: Olof.eriksson@pet.medchem.uu.se
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in any medium, provided the original work is pcells include not only the islets of Langerhans in the pan-
creas but in a broader scope also many forms of NETs. In
fact, [11C]HTP-PET was originally developed for assessment
of the AADC step in serotonin biosynthesis but has found
extensive use as a highly sensitive diagnostic tool for primary
or metastatic NETs [1]. However, the contrast to surround-
ing tissues and hence the sensitivity are affected by the rapid
MAO-A-mediated conversion of [11C]5-HT into 5-hydroxy-
[11C]indoleacetic acid ([11C]5-HIAA). Current strategies to
improve contrast involve peroral administration of the
AADC inhibitor carbidopa, which increases the biological
half-life of the tracer by reducing peripheral metabol-
ism, e.g., in the liver. However, this method induces
large individual variations in tracer metabolism and pre-
cludes comparison between examinations and therefore
therapy efficacy monitoring [5]. Increased retention of
[11C]HTP in NETs could improve the sensitivity of exam-
ination in addition to potentially visualizing smaller NETs
currently below detection threshold.
Development of new HTP analogues with improved
resistance to MAO-A degradation and with retainedan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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forward approach to potentially alter metabolic stability
while retaining [11C]HTP structurally congruent to bio-
genic HTP is to isotopically substitute the compound
with deuterium in a position that would induce a kinetic
isotope effect (KIE) large enough to deter MAO-A inter-
action. Similar approaches have previously been employed
to improve pharmacodynamics properties of radiotracers
and to increase metabolic stability against unwanted
degradation which impairs visualization of a target
tissue [7-9].
Deuterium substitution at the β-carbon adjacent to the
reaction center involved in the deamination pathway
would typically be expected to give a minor KIE of 1.1
to 1.2. While this effect would not be expected to be
particularly strong, the β-position was predicted to be
readily accessible for 11C- and 2H-labeling by only minor
changes to the original synthesis of [11C]HTP, and thus,
it would serve as a convenient test case to explore
the means of deuteration to improve MAO-A resist-
ance. A more potent position could be deuteration at
the α-carbon, which is expected to yield a primary
isotope effect that is significantly higher than the sec-
ondary KIE. However, this would require that the deuter-
ium label in α-position remain intact also after conversion
by AADC to 5-HT, which is uncertain. [1-N-11C, α,α-2H2]
L-deprenyl, a selective MAO-B inhibitor, has previ-
ously been reported to induce a KIE of 3.8 ± 1.1 in ba-
boon brain [9].
Here, we present the radiosynthesis of 5-hydroxy-L-
[β-11C2H]tryptophan ([11C]DHTP) and the preclinical
evaluation of its stability in regard to MAO-A in vitro
and in vivo, in a direct comparison with [11C]HTP.
Methods
Radiochemistry
[11C]HTP was synthesized according to the method by
Bjurling et al. [10]. The method was modified to produce
[11C]DHTP by exchanging the 11C-labeled reagent [11C]
methyl iodide for [11C2H3]methyl iodide. The deuterated
[11C]methyl iodide was obtained by reduction of [11C]
carbon dioxide with LiAl2H4 followed by treatment with
hydriodic acid at standard reaction conditions used for
[11C]methyl iodide production [11].
Purification was performed by semi-preparative high-
performance liquid chromatography (VWR LaPrep HPLC,
VWR, Radnor, PA, USA) using an Ultrasphere ODS col-
umn (Beckman, Brea, CA, USA, 5 μm, 250 × 10 mm) with
eluents A: acetic acid (17 mM)/ascorbic acid (1 mM), and
B: ethanol (99.5%). After purification, the eluents were re-
moved using rotary evaporation and the product was
reformulated in 10 mL pharmaceutical-grade solution
containing ethanol 99.5%/phosphate buffer/water (0.9/2.3/
6.8) and sterile filtered (Dynagard, 0.2 μm, 2.5 cm2 HollowFiber Syringe Filter, Microgon Inc., Laguna Hills, CA,
USA). A sample was analyzed by analytical HPLC (VWR
LaChrom Elite) using a Spherisorb column (Waters,
Milford, MA, USA, 5 μm, 4.6 × 250 mm) and eluents A:
acetic acid (17 mM), and B: acetonitrile. Both HPLC
systems were equipped with UV detectors set at 254 nm
and radio detectors (Bioscan Flow-Count PMT, Bioscan,
Washington, DC, USA).
Deuterium incorporation in [11C]DHTP was determined
using liquid chromatography-electrospray ionization-mass
spectrometry (LC-ESI-MS; Micromass Quattro Premier
triple quadrupole mass spectrometer, Waters) with positive
mode scanning and selected ion recording m/z 221.1
(=HTP +H), 222.1 (=[2H]HTP +H), and m/z 223.1 (=[2H2]
HTP +H). Data was corrected for the natural abundance
of 13C.
Cell studies
INS-1 cells (an insulinoma cell line derived from rat,
0.185 × 106 cells) or PANC1 cells (a non-endocrine line
derived from human ductal cells, 0.1 × 106 cells) were incu-
bated with 1 to 2 MBq [11C]HTP or [11C]DHTP in 1 mL
PBS for 15, 30, or 60 min at 37°C either alone (baseline)
or together with 10 μM carbidopa (inhibitor of AADC,
Karbidopa, Apoteket AB, Stockholm, Sweden), 10 μM
HTP, or 10 μM clorgyline (inhibitor of MAO-A, Sigma, St.
Louis, MO, USA). All samples were repeated in triplicate.
After incubation, the cells were filtered using washing
buffer Tris-HCl (50 mM, pH 7.4) through a Whatman
GF/C filter paper (pore size 1.2 μm; Semat International
Ltd., St. Albans, UK), using a cell harvester (Brandel,
Gaithersburg, MD, USA). The radioactivity of the cells
trapped on the filter was measured in a NaI (Tl) well
counter (Uppsala Imanet AB, Uppsala, Sweden), and the
cellular radioactive uptake was corrected for radioactive
decay. Radioactive uptake was expressed as percent of
incubation dose (%ID) per million cells.
Ex vivo organ distribution in rats
Sprague Dawley rats (n = 26, weighing 392 ± 68 g) were
housed under standard laboratory conditions with free ac-
cess to food and water. All handling and experiments were
carried out in accordance with the national guidelines and
were approved by the local ethics committee for animal re-
search. All applicable institutional and/or national guide-
lines for the care and use of animals were followed.
Rats under general isoflurane anesthesia (3.6%) were
administered with 12.0 ± 2.1 MBq [11C]HTP (n = 16) or
9.4 ± 0.6 MBq [11C]DHTP (n = 11) intravenously into
the tail vein. Subgroups of groups receiving each
tracer (n = 5 for [11C]DHTP and n = 7 for [11C]HTP)
were pre-administered with 2 mg/kg clorgyline 10 min
prior to tracer injection to inhibit MAO-A-mediated
degradation.
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tracer administration and were euthanized by CO2 30
or 60 min following injection. Tissues of interest were
immediately excised, and the radioactivity concentra-
tions were measured in a NaI (Tl) well counter and re-
lated to the administered amount of tracer and the animal
weight by standardized uptake values (SUV) to allow for
comparison between animals.
Cynomolgus PET/CT
The non-human primate experiments were carried out
in accordance with the national guidelines and were ap-
proved by the local ethics committee for animal research.
All applicable institutional and/or national guidelines for
the care and use of animals were followed. Cynomolgus
monkeys (n = 2, 7,000 and 8,900 g) were examined in this
study. Anesthesia was performed as described previously
[3]. The results of the [11C]HTP examination have been
published previously [3], but its inclusion here is merited
as a direct within-individual comparison with [11C]DHTP.
The target organ in the studies was the neuroendo-
crine pancreas, due to its importance in diabetes. For all
examinations, 8.6 to 15.7 MBq/kg [11C]HTP or [11C]
DHTP was administered intravenously and the animals
were examined over the abdomen by a dynamic PET
protocol for 90 min (33 frames; 12 × 10, 6 × 30, 5 × 120,
5 × 300, and 5 × 600 s). Each animal was examined by
both [11C]HTP and [11C]DHTP under baseline condi-
tions in the morning. After baseline examinations, each
animal was administered intravenously with 2 mg/kg
clorgyline (Sigma) dissolved in 0.9% NaCl to selectively
and irreversibly inhibit MAO-A. Each animal was exam-
ined again with [11C]HTP and [11C]DHTP 0.5 or 2.5 h
later. The reason for these time points is first to allow
clorgyline to bind to MAO-A for 0.5 h. The first isoto-
pologue examination (including dynamic abdominal
scanning and a whole-body scan) then takes 2 h. After
this time (six half-lives), almost no radioactivity from the
first administration remains and the second isotopologue
can be administered. To avoid bias in the change in ef-
fect of MAO-A inhibition over time, individual 1 was
examined first with [11C]HTP and then [11C]DHTP,
while individual 2 was examined in the opposite order.
Venous blood samples (0.2 mL) were collected at 0.5,
1, 3, 5, 10, 15, 20, 30, 45, 60, and 90 min after each injec-
tion to measure the radioactivity concentration in whole
blood and plasma. Blood samples (1.5 to 2.5 mL) were
drawn at 5, 30, and 60 min following tracer administra-
tion for analysis of tracer metabolites in plasma.
Tracer metabolite analysis of [11C]DHTP and [11C]HTP
The blood sample was centrifuged at 4,000 rpm for 2 min
at 4°C (Beckman Allegra X-22R Centrifuge, Beckman
Coulter Inc., Palo Alto, CA, USA). One milliliter of plasmawas taken and 1.0 mL of 7w/v % perchloric acid was
added to precipitate the proteins. The mixture was centri-
fuged at 13,200 rpm at 4°C for 1 min (Eppendorf 5415R
centrifuge, Eppendorf AG, Hamburg, Germany). The
supernatant was filtered through a 0.2-μm nylon mem-
brane (Corning Incorporated, Corning, NY, USA) by cen-
trifugation at 13,200 rpm at 4°C for 1 min. Ten microliters
of unlabeled 1 mg/mL HTP, HIAA, and serotonin (5-HT)
was added to the supernatant. The parent compound and
metabolites were separated by HPLC and fractionated
based on the UV signals from the added unlabeled com-
pounds. The percentage intact tracer was then assessed by
measuring the activity in each fraction using a NaI (Tl)
well counter (Uppsala Imanet AB) and correcting for
radioactive decay. The sample preparation recovery was
determined by measuring the radioactivity in the plasma,
filters, and the pellet.Image analysis
Image acquisition was performed in three-dimensional
(3D) mode and reconstructed using an iterative OSEM
VUEPOINT algorithm (2 iterations/21 subsets, in a
128 × 128 matrix, zoom 50 cm in diameter). Recon-
structed data were analyzed by PMOD (PMOD Tech-
nologies Ltd., Zurich, Switzerland). Regions of interest
(ROIs) were delineated on co-registered transaxial CT
slices. Entire organs, when possible, were delineated
on sequential slices and combined into VOIs. Organ
uptake was expressed as SUV.Statistics
Results are expressed as averages ± standard deviation
throughout. Comparison between groups was assessed
by Student's t-test. For the cell experiments, the linear
regression curves and subsequent comparisons in eleva-
tion and slope were performed in GraphPad Prism 5
(GraphPad, La Jolla, CA, USA). P < 0.05 was considered
significant.Results
Radiochemistry
[11C]HTP and [11C]DHTP were reformulated in sterile
solutions ready for injection containing 740 ± 240 and
620 ± 190 MBq, respectively, with a radiochemical purity
of more than 98%. The identities of the synthesized radi-
olabeled compounds were confirmed by comparison of
retention times with authentic HTP using HPLC equipped
with UV and radio detectors. The deuterium incorp-
oration in [11C]DHTP was determined by LC-MS;
15.0% ±2.9% contained one 2H, and 7.1% ±1.8% con-
tained two 2H. The total fraction 2H-substituted [11C]
DHTP was 22.1% ±4.7%.
Figure 1 Uptake and retention in beta cells of [11C]DHTP (left panel) and [11C]HTP (right panel). [11C]DHTP had increased retention in the
neuroendocrine cell line INS-1 compared to [11C]HTP as measured by the slope of linear regression. Inhibition of MAO-A increased the retention
of [11C]HTP at all time points, but only at a single time point for [11C]DHTP. Stars indicate increase of tracer uptake after MAO-A inhibition as
compared to baseline.
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[11C]DHTP retained affinity for AADC as its uptake in
INS-1 was completely abolished by co-incubation with
either carbidopa or HTP (Figure 1, left panel) similarly
to non-deuterated [11C]HTP. Inhibition of MAO-A had
low effect on [11C]DHTP uptake or retention (no effect
on elevation or slope of linear regression, and only sig-
nificant increase at the 15 min time point p < 0.05) com-
pared to baseline, while uptake of [11C]HTP was increased
at all time points (each individual time point p < 0.05, as
well as elevation of linear regression p < 0.05). The reten-
tion of [11C]DHTP was significantly increased compared to
that of [11C]HTP (slope of linear regression p < 0.01).
There was no difference in retention between [11C]DHTP
at baseline conditions and [11C]HTP during MAO-A
inhibition.
Negligible uptake (unaffected by inhibition of AADC
or MAO-A or by competition by unlabeled HTP) was
seen of either isotopologue in non-neuroendocrine
PANC1 cells (data not shown).Figure 2 Direct comparison of biodistribution of [11C]DHTP and [11
administration. Left panel: 30 min. Right panel: 60 min. Baseline uptake
compared to that of [11C]HTP. MAO inhibition had reduced effect on [11
(*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).Ex vivo organ distribution in rats
There was a moderate increase in pancreatic uptake
(17% at 30 min and 40% at 60 min) of [11C]DHTP
compared to [11C]HTP, but the increase was not
statistically significant. As shown previously, there is a
marked increase in retention of [11C]HTP in the
neuroendocrine pancreas after inhibition of MAO-A
(Figure 2, p < 0.0001 after 30 and 60 min). An in-
crease in pancreatic retention of [11C]DHTP was also
seen after MAO inhibition. However, the effect on
[11C]DHTP was significantly lower than that on [11C]
HTP after 60 min (16%, p < 0.05).
Cynomolgus PET/CT
We have previously shown that pancreatic uptake of
[11C]HTP in non-human primates is directly dependent on
conversion into [11C]5-HT by AADC and that degradation
and washout are mediated by MAO-A [1]. Here, the neuro-
endocrine pancreas was clearly visualized by both [11C]
DHTP and [11C]HTP both during baseline conditions andC]HTP in Sprague Dawley rats following radiotracer
of [11C]DHTP in the endocrine pancreas had a tendency to increase
C]DHTP compared to [11C]HTP. Stars indicate level of significance
Figure 3 Transaxial view of the abdomen of individual 2.
Following intravenous administration of [11C]DHTP (top left panel) or
[11C]HTP (top right panel) during baseline conditions and following
intravenous pre-treatment by 2 mg/kg clorgyline (bottom panels).
Images are summations of examinations between 10 and 90 min
and normalized to SUV = 7 (red in the scale bar to the right). The
[11C]HTP examinations have been published previously at group
level [3]. White arrows indicate the location of the pancreas.
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dynamic time-dependent uptake of the isotopologues
was virtually identical in both individuals (Figure 4,
top panels). Inhibition of MAO-A abolished the wash-
out from the pancreas throughout the duration of the
examinations, and there was no appreciable difference
in the effect of MAO-A inhibition between the deuter-
ated and the non-deuterated isotopologues. MAO-A
inhibition had no effects on retention of either [11C]Figure 4 Dynamic PET examinations of individual 1 (left panels) and i
accumulation in the pancreas of both [11C]DHTP and [11C]HTP followed by
Selective inhibition of MAO-A reduces washout of both analogues to a min
and consequently, no accumulation (under baseline conditions) or effects fro
The [11C]HTP examinations have been published previously at group level [3]DHTP or [11C]HTP in non-neuroendocrine tissues such
as the liver (Figure 4, bottom panels).
There was no statistical increase in the percentage of in-
tact [11C]DHTP compared to [11C]HTP in blood plasma
in either of the individuals (Table 1). MAO-A inhibition
increased the percentage of intact radiotracer in plasma
compared to baseline, but again there was no statistical
difference between the isotopologues.
Discussion
Improved resistance to MAO-A will potentially yield
markedly increased intracellular retention of [11C]HTP
in neuroendocrine tissues. [11C]HTP is currently used as
a universal diagnostic imaging biomarker for benign and
malignant NETs [1]. However, a higher amount of intact
[11C]HTP in plasma has been shown to improve the
tracer uptake in NETs, and patients therefore are pre-
medicated with the AADC inhibitor 100 to 200 mg car-
bidopa orally 1 h prior to the PET examination [5]. This
procedure not only improves sensitivity but also intro-
duces a new parameter that directly influences absolute
uptake in lesions: the individual time for gastrointestinal
absorption of carbiodopa. Additionally, the time from in-
gestion of carbidopa until PET examination can be vari-
able in case of delays in radiochemistry. This taken
together makes direct quantitative comparison between
examinations - even repeated scans within an individual
- impossible or difficult. Importantly, it precludes the
possibility of quantitatively monitoring treatment effi-
cacy by using SUVs in individual lesions.ndividual 2 (right panels). The examinations reveal rapid high
washout which is completed after approximately 60 min (top panels).
imum. [11C]DHTP and [11C]HTP are selective for neuroendocrine tissues,
m inhibiting MAO-A are seen in tissues such as the liver (bottom panels).
.
Table 1 The percentage of intact parent compounds in blood plasma in non-human primates
Individual 1 Individual 2
Baseline MAO-A inhibited Baseline MAO-A inhibited
Time (min) [11C]HTP [11C]DHTP [11C]HTP [11C]DHTP [11C]HTP [11C]DHTP [11C]HTP [11C]DHTP
5 89.1 89.1 95.1 95.2 92.0 90.6 95.0 96.2
30 65.0 66.7 73.3 72.6 70.1 68.9 77.0 80.6
60 50.0 53.1 54.3 58.8 56.0 52.3 63.2 65.2
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of [11C]HTP in NETs as seen in the endocrine pancreas
in Figures 3 and 4 by pre-treating patients with a clinic-
ally approved MAO-A inhibitor such as moclobemide.
This would likely improve sensitivity substantially, but
peroral administration would introduce similar individ-
ual variation to that in carbidopa. Intravenous adminis-
tration on a routine basis is counter-indicated due to the
risk of causing serotonergic syndrome due to elevated
5-HT levels in the CNS. Theoretically, development of
non-brain-penetrant MAO-A inhibitors could potentially
provide an alternative way forward, but we instead suggest
minimal re-design of the biomarker itself to achieve the
same goal in an elegant manner.
The modification to the previously published [11C]HTP
synthesis method to obtain [11C]DHTP was straightfor-
ward and involved only change in the [11C]methyl iodide
synthesis where LiAlH4 was replaced with LiAl
2H4. Des-
pite possible KIEs throughout the different synthesis steps,
there was no significant difference in radiochemical yields
between [11C]HTP and [11C]DHTP (740 ± 240 vs. 620 ±
190 MBq, Scheme 1). LC-MS analysis showed that the in-
corporation yield of 2H was moderate for [11C]DHTP with
22% containing either one or two 2H. Generally, labelingScheme 1 Radiosynthesis of [11C]DHTP. (a) i [11C2H3]methyl iodide, KOH
acid oxidase (D-AAO)/catalase, glutamic pyruvic transaminase (GTP). (c) i Tr
preparative HPLC purification.using deuterated methyl iodide is expected to give higher
incorporation of deuterium in the final product [12], but
in this case, the reversible enzymatic reaction from pyru-
vate to hydroxytryptophan is suspected to induce loss of
deuterium label. The degradative process that transforms
5-hydroxy-L-tryptophan back to pyruvate proceeds over
α-aminoacrylate, the same enzyme-bound intermediate as
in the synthetic process [13]. The reversibility allows
addition of 1H at the deuterated β-position in pyruvate
and consequently also loss of 2H when converted back
again to hydroxytryptophan.
Cell studies showed that [11C]DHTP had increased re-
tention compared to [11C]HTP (Scheme 2). Further-
more, inhibition of MAO-A by clorgyline had less effect
on [11C]DHTP as opposed to [11C]HTP. The effect still
seen (for example, at the 15 min time point) can still be
expected given that only a partial deuteration was
achieved. Importantly, inhibition of MAO-A increased
the retention of [11C]HTP to the levels seen for [11C]
DHTP under baseline conditions. This suggests that
[11C]DHTP has improved stability in regard to MAO-A-
mediated degradation in vitro, while retaining the affinity
for AADC which is crucial for preserving high sensitivity
for imaging of neuroendocrine tissues., DMF; ii solvent removal by SPE; iii HCl. (b) Tris, pH 8.3 to 9.0, D-amino



















Scheme 2 Theoretical metabolism of [11C]DHTP in neuroendocrine cells. [11C]DHTP is converted into [11C2H]5-HT by AADC. Deamination by
MAO-A, and the subsequent cellular washout in the form of [11C2H]5-HIAA, is theoretically reduced by a secondary KIE.
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the biodistribution of [11C]DHTP in rodents and espe-
cially the effect of inhibition of MAO-A. Increased re-
sistance to MAO-A should in theory result in increased
retention in tissues, which facilitates serotonin to a high
degree (i.e., the neuroendocrine pancreas in this study).
We found a tendency for increased pancreatic uptake of
the deuterated isotopologue, but this was not a signifi-
cant change. [11C]DHTP retention in the pancreas was
still markedly increased by inhibition of MAO-A, but to
a lesser degree than [11C]HTP. These results show that
the current formulation of [11C]DHTP is less sensitive
to, but still to a considerable extent metabolized by,
MAO-A in rodents. Given that only 25% of the [11C]
DHTP was deuterated and still increased retention by
17% to 40%, we estimate that a formulation of 100%
deuterated [11C]DHTP would improve the retention in
rodent pancreas by approximately 70% to 160%. More
substantial resistance against MAO-A, which may be
reached by deuteration at the α-position, potentially in-
creases the absolute uptake by up to threefold after
30 min and almost tenfold after 60 min (as seen when
inducing complete inhibition of MAO-A by clorgyline,
Figure 3).
In non-human primates, however, there was no measur-
able difference between [11C]DHTP and [11C]HTP regard-
ing baseline accumulation and retention or following
MAO-A inhibition. Here, as in the rodent, we can see the
potential of reducing degradation against MAO-A, as
retention of [11C]HTP in the endocrine pancreas is in-
creased by tenfold by inhibition by MAO-A [3]. A
similar increase in retention in APUD tissues will clearly
yield a significant improvement in diagnostic sensitivity in
the oncological setting.
PET imaging measurement data will invariably have
lower sensitivity and more noise than data acquired by
well counter measurements (in this case, ex vivo organ
distribution studies and in vitro cell studies). This is con-
ceivably one of the reasons for the lack of measurable ef-
fect in non-human primates despite promising in vitro
and small-animal in vivo results.
As we did not see any noticeable increased endocrine
retention of tracer in the PET study in non-humanprimates - most likely the most predictable for the clin-
ical situation - we decided against further evaluation in a
neuroendocrine xenograft mouse model since it conceiv-
ably could yield ‘false’ positive results in small-animal
PET imaging and ex vivo organ distribution studies,
which would not translate to imaging using less sensitive
clinical PET scanners.
We conclude that the present formulation of [11C]
DHTP (22.1% ±4.7% deuterated) is still to a major extent
degraded by MAO-A in non-human primates and that
the secondary KIE introduced by a partial deuteration of
the β-position has only a minor effect on the stability of
[11C]DHTP against this enzyme despite promising re-
sults in cells and in rodents. The small effect is likely
due to the low proportion of deuterated molecules, and
it follows that increasing the deuteration efficiency at
the β-position, or direct labeling of the α-position, may
yield improved MAO-A resistance.
Conclusions
The current study shows the feasibility of improving the
metabolic in vivo stability of [11C]HTP by minimal re-
design. Partial deuteration of the β-position yields im-
proved resistance to MAO-A-mediated degradation in
INS-1 cells and in rodent pancreas in vivo, but no appre-
ciable increased retention in non-human primate neuro-
endocrine tissue. In future studies, we aim to improve
labeling efficiency with respect to deuteration of the β-
position and attempt deuteration of the α-position to
further improve the MAO-A resistance of [11C]HTP and
increase its sensitivity as a neuroendocrine marker.
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